New eczema drug enters first human tests

NCT ID NCT07239947

Recruiting now Symptom relief Sponsor: Bambusa Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called BBT001 in healthy volunteers and adults with moderate-to-severe eczema (atopic dermatitis). The main goal is to check safety and how the body processes the drug. About 63 participants will receive either the drug or a placebo, with doses increased gradually.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Dermatology Hospital of Southern Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510440, China
Jiangsu University Affiliated Hospital
NOT_YET_RECRUITING

Zhenjiang, Jiangsu, 212001, China
Jiangxi Provincial Dermatology Hospital
NOT_YET_RECRUITING

Nanchang, Jiangxi, 330000, China
Peking University People's Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100032, China
Shandong Provincial Hospital for Skin Diseases
NOT_YET_RECRUITING

Jinan, Shandong, 250011, China
Shanghai Dermatology Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200050, China
The Second Affiliated Hospital of Wannan Medical College
NOT_YET_RECRUITING

Wuhu, Anhui, 241001, China
The Second Hospital of Anhui Medical Univesity
RECRUITING

Hefei, Anhui, 230601, China
The Second Xiangya Hospital of Central South University
NOT_YET_RECRUITING

Changsha, Hunan, 410011, China
Wuxi Second People's Hospital
NOT_YET_RECRUITING

Wuxi, Jiangsu, 214002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.